Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study

References

• Deyo RA, Mirza SK, Martin BI. Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002. Spine 2006;31:2724-7
   PubMed Web of Science ®Google Scholar
• van Tulder M, Koes B, Bombardier C. Low back pain. Best Pract Res Clin Rheumatol 2002;16:761-75
   PubMed Web of Science ®Google Scholar
• Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011;27:449-62
   PubMed Web of Science ®Google Scholar
• Hardt J, Jacobsen C, Goldberg J, et al. Prevalence of chronic pain in a representative sample in the United States. Pain Med 2008;9:803-12
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009;13:185-90
   PubMed Web of Science ®Google Scholar
• Schmidt CO, Schweikert B, Wenig CM, et al. Modelling the prevalence and cost of back pain with neuropathic components in the general population. Eur J Pain 2009;13:1030-5
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20
   PubMed Web of Science ®Google Scholar
• Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009;32:1-32
   PubMed Web of Science ®Google Scholar
• Bannwarth B. Risk-benefit assessment of opioids in chronic noncancer pain. Drug Saf 1999;21:283-96
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88
   PubMed Web of Science ®Google Scholar
• Bartleson JD. Evidence for and against the use of opioid analgesics for chronic nonmalignant low back pain: a review. Pain Med 2002;3:260-71
   PubMed Web of Science ®Google Scholar
• Nicholson B. Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain Pract 2009;9:71-81
   PubMed Web of Science ®Google Scholar
• Schroder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011;337:312-20
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kögel B, et al. (−)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-76
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future 2006;31:1053-61
   Web of Science ®Google Scholar
• Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010;11:1787-804
   PubMed Web of Science ®Google Scholar
• Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30:489-505
   PubMed Web of Science ®Google Scholar
• Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011;27:151-62
   PubMed Web of Science ®Google Scholar
• Vinik A, Shapiro DY, Rauschkolb C, et al. Efficacy and tolerability of tapentadol extended release (ER) in patients with chronic, painful diabetic peripheral neuropathy (DPN): results of a phase 3, randomized-withdrawal, placebo-controlled study [abstract]. Submitted to: American Pain Society Annual Scientific Meeting; May 16-19, 2012; Honolulu, HI
   Google Scholar
• Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010;10:416-27
   PubMed Web of Science ®Google Scholar
• Etropolski M, Van Hove I, Ashworth J, et al. Efficacy and tolerability of tapentadol extended release (ER) in patients with moderate to severe osteoarthritis or low back pain over 2 years of treatment [abstract]. Presented at: 64th Annual Postgraduate Assembly in Anesthesiology (PGA); December 10-14, 2010; New York, NY
   Google Scholar
• Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 2010;14:781-3
   PubMed Web of Science ®Google Scholar
• Bogduk N. On the definitions and physiology of back pain, referred pain, and radicular pain. Pain 2009;147:17-19
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004;108:248-57
   PubMed Web of Science ®Google Scholar
• Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-7
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
   PubMed Web of Science ®Google Scholar
• Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S22-32
   PubMed Web of Science ®Google Scholar
• Ware JE, Jr Donald Sherbourne C. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
   Google Scholar
• Selai CE, Trimble MR, Price MJ, et al. Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs. Curr Med Res Opin 2005;21:733-9
   PubMed Web of Science ®Google Scholar
• Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69-77
   PubMed Web of Science ®Google Scholar
• Haythornthwaite JA, Hegel MT, Kerns RD. Development of a sleep diary for chronic pain patients. J Pain Symptom Manage 1991;6:65-72
   PubMed Web of Science ®Google Scholar
• Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes 2003;1:29
   PubMedGoogle Scholar
• Attal N. Pharmacologic treatment of neuropathic pain. Acta Neurol Belg 2001;101:53-64
   PubMed Web of Science ®Google Scholar
• Gatti A, Sabato AF, Carucci A, et al. Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain: a prospective observational study. Clin Drug Investig 2009;29(Suppl 1):31-40
   PubMed Web of Science ®Google Scholar
• Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003;60:927-34
   PubMed Web of Science ®Google Scholar
• Watson CP, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-8
   PubMed Web of Science ®Google Scholar
• Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41
   PubMed Web of Science ®Google Scholar
• Morlion B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. Curr Med Res Opin 2011;27:11-33
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313
   PubMedGoogle Scholar
• Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99
   PubMed Web of Science ®Google Scholar
• Schroder W, Vry JD, Tzschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010;14:814-21
   PubMed Web of Science ®Google Scholar